Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570973 | 1.00 | MAOB (0.39) | MAOBMAPTRXFP1MAOACA1 | |
| SCHEMBL570888 | 0.92 | MAOB (0.39) | MAOBMAPTRXFP1MAOACA1 | |
| SCHEMBL570890 | 0.92 | MAOB (0.39) | MAOBMAPTRXFP1MAOACA1 | |
| SCHEMBL571130 | 0.89 | GPR35 (0.41) | MAOBMAPTMAOACA1CA2 | |
| SCHEMBL15166658 | 0.89 | GPR35 (0.41) | MAOBMAPTMAOACA1CA2 | |
| SCHEMBL570599 | 0.86 | MAOB (0.44) | MAOBMAPTMAOACA1CA2 | |
| SCHEMBL15166677 | 0.86 | MAOB (0.44) | MAOBMAPTMAOACA1CA2 | |
| SCHEMBL570824 | 0.86 | CYP3A4 (0.41) | MAOBMAPTMAOACA1CA2 | |
| SCHEMBL570825 | 0.86 | CYP3A4 (0.41) | MAOBMAPTMAOACA1CA2 | |
| SCHEMBL12504932 | 0.81 | DHODH (0.44) | MAOBMAPTMAOACYP1B1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815940-B2 | Coumarin-chalcones as anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-26 | — | — | US | claimed |
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-08-15 | — | — | US | claimed |
| US-8815940-B2 | Coumarin-chalcones as anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-26 | — | — | US | disclosed |
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-08-15 | — | — | US | disclosed |
| EP-2601183-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | Council Of Scientific & Industrial Research (IN) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012017454-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | HCCS, XPO5, CIAPIN1 | MAOB 4231/4885MAPT 3772/4885RXFP1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.